Voloridge Investment Management LLC Reduces Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Voloridge Investment Management LLC lowered its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 71.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,483 shares of the biopharmaceutical company's stock after selling 83,499 shares during the quarter. Voloridge Investment Management LLC's holdings in Ocular Therapeutix were worth $286,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC boosted its position in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after acquiring an additional 138,441 shares during the last quarter. SG Americas Securities LLC lifted its position in Ocular Therapeutix by 58.7% during the fourth quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company's stock valued at $612,000 after purchasing an additional 26,511 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Ocular Therapeutix by 11.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock worth $285,000 after buying an additional 3,347 shares in the last quarter. Deltec Asset Management LLC increased its holdings in shares of Ocular Therapeutix by 0.6% in the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock worth $22,344,000 after buying an additional 16,300 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Ocular Therapeutix by 2.7% in the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company's stock valued at $1,824,000 after acquiring an additional 5,682 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on OCUL. JMP Securities set a $19.00 target price on Ocular Therapeutix in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price on the stock. William Blair started coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating on the stock. Finally, Needham & Company LLC dropped their target price on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Ocular Therapeutix Trading Up 2.7%

Ocular Therapeutix stock traded up $0.22 during trading hours on Tuesday, hitting $8.33. The company had a trading volume of 2,951,070 shares, compared to its average volume of 1,406,612. The firm has a market cap of $1.33 billion, a P/E ratio of -6.31 and a beta of 1.51. The company has a 50-day moving average price of $7.39 and a two-hundred day moving average price of $7.89. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The firm had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. On average, sell-side analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,219 shares of the company's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the transaction, the insider now owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of the stock in a transaction dated Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 29,079 shares of company stock valued at $208,739. 2.30% of the stock is currently owned by insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.